KD-035 is under clinical development by Oncon and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KD-035’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KD-035 is under development for the treatment of solid tumors and metastatic colorectal cancer. It is a monoclonal antibody acts by targeting VEGFR-2. It is administered through parenteral route.
Oncon is a biotechnology company focused on developing antibody drugs for cancer treatments. Oncon is headquartered in Moscow, Russia.
For a complete picture of KD-035’s drug-specific PTSR and LoA scores, buy the report here.